Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of 7 per equity share.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences' Board, at its May 9, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditors issuing an unmodified opinion. The Board recommended a Final Dividend of ₹7 per equity share (70% on face value of ₹10) for FY25, subject to shareholder approval at the upcoming AGM. On a standalone basis, FY25 revenue from operations was ₹2,864.66 million (vs ₹2,851.55 million in FY24), while profit after tax rose ~17% to ₹318.42 million (vs ₹271.59 million), with EPS at ₹37.43 (vs ₹31.93). Consolidated PAT grew ~36% to ₹288.26 million. The Poultry Healthcare segment led growth. The Board also appointed Shah & Shah Associates as Secretarial Auditors for five years (FY26-FY30).
The recommended ₹7/share dividend is an increase over the prior year's payout, signaling continued and improving shareholder returns alongside earnings growth. The clean audit opinion and strong PAT growth support positive investor sentiment, though the dividend remains subject to AGM approval.